Sentence: Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab ( 5 mg/kg body weight i.v . every 21 days ) and oral capecitabine ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 .
Drug combination annotation:
[{'class': 'NEG', 'spans': ['bevacizumab', 'capecitabine'], 'is_context_needed': True}]